ACTACTSC

DPP v Kustic

[2026] ACTSC 309

Supreme Court of the ACT|2026-08-21|Before: Taylor J

View on the ACT Courts

At a glance

Source facts

Court

Supreme Court of the ACT

Decision date

2026-08-21

Before

Taylor J

Catchwords

CRIMINAL LAW – JURISDICTION, PRACTICE AND PROCEDURE – Judgment and Punishment – Sentence – large commercial drug supply across Australia – offender who acted above two others – parity – proceeds of crime exceeding $1,000,000 – consequences of large-scale drug supply – subjective case – psychiatrist report – good prospects of rehabilitation – lengthy remand period prior to sentence

Source

Original judgment source is linked above.

Catchwords

CRIMINAL LAW – JURISDICTION, PRACTICE AND PROCEDURE – Judgment and Punishment – Sentence – large commercial drug supply across Australia – offender who acted above two others – parity – proceeds of crime exceeding $1,000,000 – consequences of large-scale drug supply – subjective case – psychiatrist report – good prospects of rehabilitation – lengthy remand period prior to sentence

Judgment

Source: the ACT Courts (www.courts.act.gov.au). Converted to plain text by ZoeLaw. Not the official version.

SUPREME COURT OF THE AUSTRALIAN CAPITAL TERRITORY

Case Title: DPP v Kustic Citation: [2026] ACTSC 309 Hearing Date: 31 July 2026 Decision Date: 21 August 2026 Before: Taylor J Decision: At [134] Catchwords: CRIMINAL LAW – JURISDICTION, PRACTICE AND PROCEDURE – Judgment and Punishment – Sentence – large commercial drug supply across Australia – offender who acted above two others – parity – proceeds of crime exceeding $1,000,000 – consequences of large-scale drug supply – subjective case – psychiatrist report – good prospects of rehabilitation – lengthy remand period prior to sentence Legislation Cited: Crimes Act 1900 (ACT), s 171(2) Crimes Act 1914 (Cth), ss 3LA, 19 Crimes (Sentencing) Act 2005 (ACT), s 62 Criminal Code 2002 (ACT), s 603 Criminal Code Act 1995 (Cth), s 400.3 Medicines, Poisons and Therapeutics Goods Act 2008 (ACT), s 26 Cases Cited: Braisse v The King [2025] WASCA 161 Bui v The Queen [2015] ACTCA 5 DPP v Al-Mofathel [2024] ACTSC 117 DPP v Bobb [2025] ACTSC 491 DPP v Doughty [2023] ACTSC 397 DPP v Kelleher [2026] ACTSC 89 DPP v Martens [2025] ACTSC 24 DPP v Torbert [2023] ACTSC 332 R v White [2022] ACTSC 178 Tan v the State of Western Australia [2019] WASCA 112 Parties: Director of Public Prosecutions Michael Adam Kustic (Offender) Representation: Counsel M Howe (DPP) B Barrack (Offender) Solicitors ACT Director of Public Prosecutions Krayem and Co (Offender) File Number: SCC 377 of 2024 TAYLOR J: Introduction

The offender, Michael Adam Kustic, is to be sentenced for the following offences, having entered pleas of guilty on 17 February 2026: (a) Count 1 (CC2023/12189) supply anabolic steroids contrary to s 171(2) of the Crimes Act 1900 (ACT), which has a maximum penalty of 500 penalty units, 5 years of imprisonment or both. (b) Count 2 (CC2023/12264) traffic in large commercial quantity of a controlled drug, namely psilocin contrary to s 603(1) of the Criminal Code 2002 (ACT), which has a maximum penalty of imprisonment for life. (c) Count 3 (CC3034/8065) traffic in large commercial quantity of a controlled drug, namely tetrahydrocannabinol (THC), contrary to s 603(1) of the Criminal Code 2002 (ACT), which has a maximum penalty of imprisonment for life. (d) Count 4 (CC2024/3237) Fail to comply with an order under s 3LA, contrary to s 3LA(6) of the Crimes Act 1914 (Cth), which has a maximum penalty of 600 penalty units, 10 years of imprisonment or both. (e) Count 5 (SCCAN 19/2026) deal with proceeds of crime exceeding $1,000,000 or more contrary to s 400.3(1) of the Criminal Code Act 1995 (Cth) which has a maximum penalty of imprisonment for 25 years, 1500 penalty units, or both.

DPP v Kustic [2026] ACTSC 309 | Case summary | Zoe

The offender and a co-offender Mr Thomas Kelleher knew each other through the gym. For years, both had been enthusiastic users of anabolic steroids.
In 2022, the offender sold the panel beating business he had owned for 12 years and shortly afterwards started supplying anabolic steroids. By August 2023 his business, OzPharmlabs, had become a successful and sophisticated syndicate.
The offender was the boss of OzPharmLabs. He operated the OzPharmlab Threema1 handle through which customers would make contact with the syndicate. He was also in charge of arranging the re-supply of the syndicates stock and paying other members of the syndicate a 'wage'.
Thomas Kelleher stored the illicit stock in his garage at [redacted] O'Connor. This was the warehouse out of which the group operated. Kelleher would pack the orders there before they were posted in street mailboxes.
Another co-offender, Mr James Martens was a 'runner'. Martens went by the nickname "Thirty" and his main job was to pick up deliveries from fraudulently obtained post office boxes as well as post the packed orders. Marten's also dealt directly with a supplier of illicit substances named Wang, who paid Martens directly into a fraudulent bank account.
[redacted]
On occasion Martens also packed orders, packed pills into bottles, and made at least one run to Melbourne to pick up stock and deliver it to the hub [redacted] in O'Connor.
Day-to-day operation of the business and communications between the members of the syndicate happened over various Threema group chats.
On 29 September 2023, the offender boasted about his work:
Customers paid by either depositing money into bank accounts operated by the offender or through cryptocurrency. Salesmen for the business would regularly be asked to empty their cryptocurrency wallets into 'wallets' controlled by the offender.
The business and personal bank accounts operated by the offender and Martens had been fraudulently opened in other people's names and through using identification material belonging to other persons.
Consistent among the bank accounts was a steady stream of money transfers from multiple different names, many on the same day. The transfers range from hundreds of dollars to thousands of dollars and reference invoice numbers. On several occasions the fraudulent accounts directly transferred money into the offender's personal bank account.
Between 14 July 2022 and November 2023, $1,811,899.78 was credited into the various fraudulent bank accounts operated by the offender (Proceeds of crime more than $1 million).
The salesmen would regularly be asked to empty their cryptocurrency wallets into 'wallets' controlled by the offender.
Once payment was received from an OzPharmlabs customer, the salesmen would send through the orders to the offender and Kelleher on Threema. The orders would be packed at [redacted] before being posted in street mailboxes.
The offender also maintained multiple post office boxes fraudulently opened in other people's names into which deliveries would be received
On 8 December 2023, police executed search warrants across multiple properties connected to the syndicate.

Between April 2022 and October 2023, police executing various search warrants seized steroids with OzPharmLabs branding as well as communications from customers through Threema with the handle 'AU OzPharmLabs AU'. Some of these customers were identified as having made deposits into the fraudulent bank accounts operated by the offender.
Police began actively investigating this OzPharmLabs syndicate in August 2023 under the codename Operation Athas.
As part of the investigation, police were granted permission to conduct a major controlled operation. The controlled operation included telephone intercepts, controlled buys, and physical surveillance, before ultimately the execution of a number of warrants as part of the resolution of the matter. The offender withdrawing money from ATMs
On 19 September 2023, The offender drove to the Westpac ATMs in Dickson and withdrew thousands of dollars in multiple transactions using several different cards in different names: About 9:13pm, THE OFFENDER placed AMP Limited bank card [redacted] in the name of [redacted] into the ATM and withdrew $1000.00; About 9:14pm, THE OFFENDER placed Commonwealth Bank of Australia (CBA) bank card [redacted] in the name of [redacted] into the ATM and withdrew $1500.00; About 9:15pm, THE OFFENDER placed CBA bank card [redacted] in the name of [redacted] into the ATM and withdrew $2000.00; and About 9:16pm, THE OFFENDER placed National Australia Bank (NAB) bank card [redacted] in the name of [redacted] into the ATM and withdrew $2000.00
The offender did the same thing on 25 September 2023: About 8:13pm, THE OFFENDER placed CBA bank card [redacted] in the name of [redacted] into the ATM and withdrew $2000.00; About 8:14pm, THE OFFENDER placed CBA bank card [redacted] in the name of [redacted] into the ATM and withdrew $2000.00; About 8:15pm, THE OFFENDER placed NAB bank card [redacted] in the name of [redacted] into the ATM and withdrew $2000.00; About 8:16pm, THE OFFENDER placed CBA bank card [redacted] in the name of [redacted] into the ATM and withdrew $1000.00; About 8:17pm, THE OFFENDER placed AMP Limited bank card [redacted] in the name of [redacted] into the ATM and withdrew $1000.00; and About 8:18pm, THE OFFENDER placed CBA bank card [redacted] in the name of [redacted] into the ATM and withdrew $1500.00. Controlled Buy One (Supply anabolic steroids)
On 26 October 2023, an AFP covert operative made contact with OzPharmLabs via Threema. The user replied with confirmation and sent through a "recent stocklist".
On 27 October 2023 the covert operative placed an order for – 2 x Test 325 2 x Tren Enanthate
On 30 October 2023 the undercover operative deposited $440 into a Commonwealth Bank of Australia account provided by OzPharmLabs: [redacted]
That account is controlled by the offender and is one of the accounts from which he withdrew cash on 19 and 25 September 2023.
The account had an attached ABN for a business in the name of Macca Massage, as well as an address, licence and email address attributed to [redacted].
While it was the correct licence number, the real [redacted] had not lived at the stated address for years and had never used that email address nor associated with that business.

On 14 November 2023, James Martens attended Kelleher's address at [redacted]. A short time later he left and drove to the post boxes on Sullivan Creek Road at ANU. He posted 42 packages into both the red and yellow post boxes.
With the help of Australia Post, police accessed the post boxes and identified several parcels suspected to have been posted by Martens. The parcels were taken to a sorting facility in Mitchell and were later seized by police.
The packages were addressed to different people across Australia and labelled as coming from businesses, such as the Parramatta Tackle Shop. Most of the parcels contained anabolic steroids and declared substances. A list of the substances contained within packages seized is found at Annexure A.
Two of the packages each contained 15 bars of 'PSI' branded chocolate cookies, totalling 30 bars. These chocolate cookies were described to have a net weight of 60 grams, and contain '4G PSILOCYBIN MUSHROOMS'. The total weight of the bars was approximately 1.8 kgs. The same product was later seized during a search warrant at [redacted] and confirmed by analysis to contain the controlled drug Psilocine.
Also amongst the 42 parcels was 2 bags of a product described as 'Bliss Bites Watermelon' with the further description, 'Premium infused THC Gummies'. The following picture depicts the packaging of these two products:
The same product was later seized during a search warrant at [redacted] and confirmed by analysis to contain the controlled drug THC.
The same product was later seized during a search warrant at [redacted] and confirmed by analysis to contain the controlled drug THC.
On 20 November 2023, the following conversation was intercepted between The offender and Kelleher: THE OFFENDER: Then I've got this other cunt. You remember that 30 mushroom chocolate you sent out? KELLEHER: Yeah. THE OFFENDER: He's like, what are you going to do about this package? I'm like mate, it's only been 5 business days. You've got the tracker, call Auspost. KELLEHER: Hasn't it got there? That was like 2 weeks ago. THE OFFENDER: Nar it was only last week. KELLEHER: That's weird. I would have dumped those big ones myself, just to make sure they were out. Fuck the post has been shit hasn't it? Yeah I put 15 and 15 I think. Should be alright. Maybe I should have done 10, 10 and 10. Controlled buy four (supply anabolic steriouds)
On 21 November 2023, an undercover operative placed an order with OzPharmlabs on Threema for: Primobolan Enanthate 100mg/ml DBol 20mg x 100 tabs Nandralone Phelyproionate 100mg/ml
The operative was quoted $540 for the order and provided with a cryptocurrency wallet address into which the operative paid the requested amount.
On 29 November 2023 Senior Constable Owen Patterson collected the package. The package contained - 1 x Primobolan 100 1 x NPP 100 Dianabol
The products were tested and found to contain anabolic steroids.

The offender was often on his phone talking to friends and family. On 25 October 2023 he had the following conversation with his partner: FEMALE ONE: Maybe you all need to just be like legal and then - and then you won't have these issues. (laughing) THE OFFENDER: I mean the government shouldn't fucking tax these small business so much and you wouldn't have to fucking do it. FEMALE ONE: You think the government - - - THE OFFENDER: You can actually make some money out of the business. FEMALE ONE: There's nothing you can do about the government brother. (laughing) THE OFFENDER: No, but that's what I'm saying, maybe they shouldn't tax small business so much and actually do something for us. FEMALE ONE: It just has to be the government (indistinct) with you. THE OFFENDER: Yeah. FEMALE ONE: And do it legally this time, making the government work with you. (laughing)
On 3 November 2023, the following conversation was intercepted - THE OFFENDER: I made - I profited nearly two million dollars this year, you don't do that without drugs. MALE ONE: Yeah, no, no. Fuck, good on you, bro, from fucking thirty grand a year as a panel beater to two million a year, fuck you're kicking goals, eh. Oh, oh, (laughing)
The following conversation is from 16 November 2023: THE OFFENDER: I just *indistinct* that 'Thirty' cunt, because he's working for me, do you know what that cunt earns nearly a week now?. CALLER: I'd hate to know. THE OFFENDER: Do you wanna know? CALLER: 5? THE OFFENDER: Double it CALLER: 10? THE OFFENDER: Some weeks even more, 20. And living week to week bro. I swear to you Search warrants
On 8 December 2023, police executed search warrants at multiple properties connected to the syndicate.
At [redacted], O'Connor, where Kelleher lived and which was the packing and distribution hub of the business, police found and seized over two days- (a) Significant number of boxes of anabolic steroids and pharmaceutical drugs (Supply anabolic steroids [continued]; Additional offence of supplying a declared substance [continued]). (b) 40 blocks (a total weight of 2.14 kgs) of 'PSI' branded mushroom chocolate bars containing Psilocine (Trafficking in large commercial quantity of Psilocine [continued]). 30 of the chocolate bars were located in a fridge within the garage.2 (c) Numerous items containing THC (a total weight of over 21 kgs) (Trafficking in large commercial quantity of THC [continued]) (d) $66,095 in cash (e) Cryptocurrency hardware wallets and cryptocurrency (f) Australia post parcel packages Photographs of Kelleher's garage
The total street value of the drug items seized, based on prices advertised by OzPharmLabs during the controlled buys, is $8,919,940. A list of the substances contained within packages seized is found at Annexure C.
At [redacted], Googong, NSW, where the offender had recently moved into with his partner [redacted] police found and seized - (a) $293,275 in cash (Proceeds of crime more than $1 million [continued]) (b) Boxes of pharmaceutical drugs both open and sealed (c) Vials of anabolic steroids (d) Name brand watches (e) Louis Vuitton bags and wallets (f) In one Louis Vuitton satchel identified by the offender as his bankcards in the names of the following people - (i) [redacted], (ii) [redacted], (iii) [redacted], (iv) [redacted], (v) [redacted], (vi) [redacted], (vii) [redacted], (viii) [redacted] and, (ix) [redacted], (g) Two cryptocurrency hardware wallets (h) Nine mobile phones (i) Phones with sticky notes attached to them in the names of [redacted].
During the search warrant, the offender was asked for access to the Apple iPad he was holding when police arrived, an Apple iPhone he had attempted to conceal under a pillow, the [redacted] mobile phone, the [redacted] mobile phone, the [redacted] mobile phone, the [redacted] mobile phone and a black Trezor cryptocurrency hardware wallet. He did not provide access. This conduct is not subject to the 3LA charge.

The significant maximum penalties which apply, as a yardstick, reflect the gravity of the offending. The most serious offences, the trafficking offences, have a maximum penalty of life imprisonment.
The Court of Appeal in Bui v The Queen [2015] ACTCA 5 set out the factors which inform an assessment of the objective seriousness of a trafficking offence. As with the co-offender (DPP v Kelleher [2026] ACTSC 89 at [38]), I consider these factors are also instructive in the case of the offences involving the supply of anabolic steroids and declared substances. The Court in Bui stated at [41]: The role of the accused is an important consideration, those whose level in the operation is at a higher level of the hierarchy being more culpable: MacDonnell at 50; While, as decided in Wong v The Queen at 609; [67]-[70], the weight of the amount of drug is not of chief importance in determining the appropriate sentence, it remains a relevant factor, particularly in the context of the harm from its distribution effects: R v Bezan (2004) 147 A Crim R 430 at 438; The motivation for the offence is highly relevant, the purpose of profit being a more serious matter: R v Speechly (2002) 133 A Crim R 26 at 30; R v Day (1998) 100 A Crim R 275 at 277. The prosecution made the same concessions in this matter with respect to the trafficking offences as were made in Kelleher. I made the following observations at [40]-[42] which have equal force in this matter: The prosecution conceded two aspects of the trafficking offences relevant to consideration of their objective seriousness and of the significance of general deterrence and community protection. First, that the offences involved drugs with a capacity for profit which was not as financially rewarding as with other illicit drugs. Secondly, that the drugs involved did not have the same harmful effects on the community as other illicit drugs, such as methamphetamine. These concessions are consistent with the approach taken by the Victorian Court of Appeal in DPP v Maxwell [2013] VSCA 50 where the court accepted that a “reward differential” as between substances could reasonably justify lower sentences for offending which involved substances yielding lower reward on the basis that it was a proper matter to consider with respect to culpability, further observing at [34]-[36]: Sentencing judges are also justified in treating the scale of the anticipated reward as relevant to considerations of deterrence, both specific and general. As has often been said, the sentence to be imposed for a drug importation (or trafficking) offence must signal both to the offender, and to other would-be offenders, that the potential financial rewards to be gained from such activities are outweighed by the risk of severe punishment. Obviously enough, the greater the anticipated reward, the more powerful the deterrent message must be. The converse is also true. There is another reason why general deterrence may be seen to be of increased importance if the anticipated reward from dealing in illicit drugs is high. Where the potential to reap large profits from dealing in a particular proscribed drug is great, the potential for the commission of offences involving that drug — with corresponding risk of harm to the community — might be regarded as greater. Thus, considerations of general deterrence and community protection are of more significance in those cases than in a case like the present. To treat a low-reward drug like GBL differently for sentencing purposes is in no way inconsistent with the statutory assumption that a commercial quantity of drug A is to be viewed for sentencing purposes as being just as harmful as a commercial quantity of drug B. But it is to recognise that the very high maximum penalties fixed for offences involving a commercial quantity (or more) reflect a legislative intention to visit very heavy punishment on drug profiteers. Plainly enough, KM does not fall into that category. (Citations omitted.) With respect to the offence involving declared substances, the prosecution drew my attention to Ede v Hyde [2014] ACTSC 305 at [6] in which Penfold J observed the following with respect to offences committed pursuant to the Medicines, Poisons and Therapeutics Goods Act 2008: The relevant object furthered by the prosecution of Mr Ede seems to have been that set out in s 6(1)(c), to minimise “the diversion of regulated substances for abuse”. While some of the other specified objects of the MPTG Act are directly related to the safety of individual members of the public, the diversion of regulated substances for abuse seems to raise issues that are broader than just the direct dangers of unauthorised consumption of the relevant substances. Those issues may include such things as the danger possibly posed to the community by people who have consumed mind-altering drugs without a good medical reason, affecting the availability of the substances for legitimate use and effectively diverting any public subsidies incorporated in the price of medicines supplied on prescription.
The first thing to observe is that the offences are ‘rolled up’. This means they are more serious examples of the offence than if only one instance of trafficking conduct was captured.
I am satisfied that the offender was directing co-offenders Kelleher and Martens (DPP v Martens [2025] ACTSC 24) and was ‘in charge’ of the arm of the operation which involved them. For their part, the offender paid the co-offenders a wage. The offender arranged for the supply of the ‘product’ sold by his arm of the operation. I accept that the offender himself was operating below those closer to the controlling mind of the entire operation.
The enterprise being controlled by the offender was sophisticated and well organised operating online through an encrypted messaging service. The enterprise involved large scale distribution of steroids, declared substances and other illicit substances.
I am satisfied that the offender was driven by greed which was in part fuelled by a desire to provide financial security for his family but which saw the offender make a substantial profit demonstrated by his purchase of luxury items.
The quantity of Psilocine (admixture) was approximately 3.76 kgs (almost double a large commercial quantity). The packaging recorded that there was 4g of the controlled drug which was 6.7% of the admixture. There was no purity analysis conducted. The estimated value of the controlled drug was $17 500.
The weight of the THC (admixture) was over 21 kgs (over 10 times a large commercial quantity). There was no analysis of purity. The estimated value of the controlled drug was $78 000.
The ‘street value’ of the declared substances and steroids together was almost 9 million dollars.
When sentencing the offender for the supply anabolic steroid offence I must take into account the offence of ‘supply declared substance’ (the scheduled offence). The scheduled offence has a maximum penalty of 500 penalty units, 5 years of imprisonment or both. The scheduled offence was an objectively serious offence and this was a serious example of the offence for reasons I have already recorded. The effect of the scheduled offence will see a more severe penalty imposed on the principal offence than otherwise would be the case though I acknowledge the principal and scheduled offence both occurred in the context of the overall enterprise.
The proceeds of crime offence involved a substantial sum of money, almost $2.5 million in total, consisting of the following sums of money: (i) $1,811,899.78 from various fraudulent bank accounts operated by the offender; (ii) $375,144.06 in the offender’s personal bank account; and; (iii) $293,275.00 cash seized during the execution of a search warrant at the offender’s home.
The proceeds of crime offence is a ‘rolled up’ count – capturing money dealt with by the offender over a protracted period (17 months) in his personal bank accounts, fraudulent bank accounts operated by him (created by identification information which did not belong to the offender), and cash found at his property.
The offence captures almost 3000 transfers to bank accounts controlled by the offender in the period of the offending. The offender was the direct beneficiary of what was, on any view, a vast sum of money and solely in control of the funds. The deliberate nature of the conduct and the period over which it occurred reflect a high degree of criminality. The prosecution accepted that the offence did not involve “for the most part, funds derived from the respective trafficking/supply offences” noting those offences relate to the period between 25 October 2023 and 9 December 2023 and the proceeds of crime offence “covers an additional 15 months, dating back to 15 July 2022”.
The failure by the offender to comply with the ‘3LA’ order occurred some months after his arrest and remand. The demand related to a cryptocurrency device. Whilst I accept the submission that the failure to comply did not result in significant frustration of the offences now for sentence, the offender’s refusal to comply did not occur in ‘the heat of the moment’ of his arrest or during the execution of a search warrant. The refusal was the result of a deliberate decision made by the offender to frustrate police enquiries into his activities and thereby deliberately expose himself to an additional offence. This represents the kind of ‘calculated decision’ contemplated by Mossop J in DPP v Al- Mofathel [2024] ACTSC 117 at [52]. As his Honour observed, general deterrence is a compelling sentencing consideration for this offence to “deter offenders from making the calculation that they will receive a lesser penalty by failing to comply with the order than they would if they complied and their phone could be interrogated”.

The following is a summary of the information provided in an Intensive Correction Order Assessment Report (ICOAR) dated 19 June 2026 and a report from Dr Richard Furst dated 13 July 2026 as well as references provided by the offender’s partner and mother. Early life and family circumstances
The offender is 41 years of age. He has no criminal history. He identified as Aboriginal through his mother, though had limited information about his cultural connections to offer the author of the ICOAR. He is the eldest of four children from his parents’ marriage. His parents are still married to each other and continue to support him.
The offender was exposed to “severe abuse, neglect and cumulative trauma” as a child. He was sexually abused by an uncle for several years. He did not disclose this abuse to anyone until he was an adult. He was subjected to “constant” and severe physical discipline by his father who was an alcoholic. He was also exposed to severe violence, which was perpetrated by his father against his mother and his siblings.
The offender’s mother corroborated the offender’s report of his childhood and noted the profound effect on the offender of his childhood experiences, as well as her own feelings of guilt for leaving the offender in the care of his uncle when she was experiencing violence.
The offender was married for over a decade. The breakdown of his marriage six years ago was emotionally and financially stressful for him. The offender has been with his current partner for 6 years. She has two children from a previous relationship. She gave birth to her child with the offender whilst he was remanded in custody in relation to these offences. Their daughter is now 2 years old and the offender has had some contact with her at the AMC. The offender plays a father figure role to his partner’s children and has a close bond with them. Education and employment
The offender completed a panel beater apprenticeship after his schooling and received recognition for his skill receiving ‘apprentice of the year’ award for three consecutive years.
For many years, the offender owned and operated a successful smash repair business and expressed his intention to return that industry upon his release and his confidence that he would be readily able to do so given his success in the past. His business began to struggle during the pandemic and the offender sold it in 2022.
The offender has been employed as a sweeper at the AMC. Drug use and mental health
Consistent with the ICOAR, Dr Furst recorded that the offender has a history of depression dating back to his early teens which became more prominent in his mid to late twenties. This coincided with his disclosure of the sexual abuse he had suffered as a child. The offender managed his low mood by suppressing his emotions and working excessive hours. He has some history of suicidal ideation and has seriously attempted suicide on two occasions as an adult.
The offender became “depressed and despondent” in 2021. Dr Furst noted this “dark period” came after the breakdown of the offender’s marriage, the struggles with his business during the pandemic as well as the offender’s realisation that he needed to confront the long-terms effects of the childhood sexual abuse he suffered.
The offender sought to “numb” his negative emotions and his intrusive memories of the childhood abuse. He has a history of drug use which dates to his teens and commenced cocaine and amphetamine use in his late twenties “to help cope with work stress and to block out and/or overcome negative emotions”. From his mid thirties the offender used prescribed and non-prescribed steroids. A significant back injury from weightlifting saw the offender develop dependence on prescribed and illicit substances including a period of daily cocaine use.
The offender commenced counselling and treatment in 2022 with respect to his unresolved trauma and depression which included EMDR (eye movement desensitisation and reprogramming), meditation and yoga practice. The offender reported finding yoga particularly helpful with anxiety and stress. The offender was engaged in this treatment and support up until his arrest for these offences. The offender has expressed his desire to continue to engage in this support upon his release.
He was prescribed antidepressant medication Fluoxetine in 2020 and has used it since then except for a short period at the end of 2023, beginning of 2024 when he did not take it. The offender has received medication whilst in custody for intervertebral disc bulges in his lower lumbar spine as well as flattened disc in the lower cervical spine. Because of his remand in custody scheduled surgery in 2024 did not go ahead. The offender has initiated weight training and therapeutic yoga whilst on remand.
Dr Furst recorded that the offender was “struggling emotionally” at the time he engaged in the offending and felt pressure to provide for his family financially. The offender reported to Dr Furst that he was driven to engage in the offending to enhance his capacity to provide for his partner and her children and that he did not intend to “hurt people”. He explained that he approached the illegal enterprise on the basis that it could “help by supplying the drugs/pharmaceuticals that people needed at a lower price”.
The offender stated to Dr Furst that he regrets his actions describing his offending as “the biggest mistake I made was thinking that it wasn’t that bad”. The offender told Dr Furst that he is “ashamed and embarrassed” and he did not ever think that “he would end up in here [in gaol]”.
Dr Furst diagnosed the offender with complex post-traumatic stress disorder (CPTSD) with the ‘main precipitant’ being the protected period he was subjected to child sexual abuse. Dr Furst also concluded that the offender met the diagnostic criteria for major depressive disorder and substance use disorder.
Dr Furst determined that the offender, in the face of the childhood abuse he suffered, developed “maladaptive” means of coping which included use of drugs and alcohol. The offender’s depression was compounded by his chronic physical pain and his low testosterone (both of which are associate with depression). Dr Furst recorded: His decision to sell his business in 2022 took place in the context of his still being depressed, as he was seeing a psychologist and having EMDR that year as well as consulting a psychiatrist to try and get better. In all the circumstances, he remained symptomatic in terms of his depression, anxiety and long-term effect of trauma throughout the course of his offending, as described in the agreed facts…People who suffer from depressed mood and anxiety tend to overestimate negative factors and stresses in their lives compared to people who are not depressed or anxious. Michael’s depressive illness was characterised by cognitive impairment, those factors likely affecting his decision making.
Dr Furst recorded that there is a much higher rate of mental ill-health in adults who were the victim of childhood sexual abuse as well as experiencing a significantly higher rate of alcoholism and drug abuse. For this offender his depression, anxiety, CPTSD and drug use all had a “negative impact on his level of function and decision making” when he engaged in the offending conduct.
Dr Furst recommended that the offender continue with the treatment he was engaged in when he was arrested, continue with medication (though suggested a different medication than Fluoxetine) and be supported to continue his study.
Dr Fust concluded that the offender was a lower risk of re-offending and had good prospect of rehabilitation citing numerous pro-social factors including the offender’s motivation to address his mental health, drug use and his physical and psychological wellbeing.
Dr Furst considered that the offender would experience custody “more onerously” than a person who did not have his disorders. The stress of being incarcerated increases the risk that he would relapse into a more acute phase of anxiety, depression and CPTSD.
The ICOAR recorded that the offender has not formed close relationships in custody though has “actively” encouraged pro-social behaviour among younger detainees. The offender has ceased all substance use whilst on remand and completed the Solaris Therapeutic Community Program. The offender was described as possessing a “clear intention” to engage in therapeutic support upon his return to the community and motivated to address his trauma history and be a good father. He was assessed as suitable for ‘low to medium level of supervision’ and suitable for an intensive correction order (ICO).

The offender’s adverse childhood experiences, his mental ill-health and his drug use as an adult are inextricably linked. The evidence demonstrated that the offender’s abuse of prescription and illicit substances was driven by a desire to ‘numb’ his negative emotions and drive out the intrusive memories of the abuse he suffered as a child. Like many victims of child sexual abuse, the offender did not disclose the abuse he suffered until he was an adult. I am satisfied that the offender’s decision making and functional capacity were diminished because of his mental ill-health.
The prosecution, appropriately in my view, accepted that the offender’s traumatic childhood experience as well as his mental ill-health should operate to reduce his moral culpability. The effect of that finding is a matter to which I shall return when considering the various purposes of sentencing.
I am satisfied that the offender is genuinely remorseful for his offending conduct. This is consistent with the observations made by the author of the ICOAR, Dr Furst as well as the offender’s partner and mother. The offender expressed remorse in a ‘letter of apology’. Of course, care should be taken when assessing untested expressions of remorse, but in this instance those expressions were consistent with other material and with the offender’s exemplary conduct whilst in custody.
The offender has completed 12 months of tertiary pathway entry studies to university and 6 months of study in business/commerce in 2024/2025 via correspondence whilst in custody. He has achieved sobriety. He is employed in a trusted position in the AMC. He has no criminal history. He has a supportive partner and family as well as stable accommodation available to him. He has consistently expressed a desire to continue to access support and treatment with respect to his psychological wellbeing and his use of illicit substances. The offender has become a father whilst he has been on remand a goal he had desired for many years. I accept that this serves as a considerable motivating factor for him.
The offender presents with good prospects of rehabilitation.

Co-offender Martens was sentenced for his part in the criminal enterprise on the basis that he was a ‘runner’ and dispensable in the context of the operation. Co-offender Kelleher was sentenced on the basis that he was significantly involved in the enterprise though operating entirely at the direction of the offender. Co-offender Kelleher was sentenced to a total period of imprisonment of 4 years, 11 months and 22 days. A non-parole period of 2 years and 3 months was set. The individual sentences imposed on Mr Kelleher were as follows: (i) Traffic in large commercial quantity of Psilocine: 2 years, 5 months and 11 days of imprisonment (reduced from 3 years and 6 months); (ii) Trafficking in a large commercial quantity of THC: 2 years, 1 month and 6 days of imprisonment (reduced from 3 years); (iii) Supply steroids (taking into account two scheduled offences namely, possess offensive weapon and money laundering) : 1 year and 9 months of imprisonment (reduced from 2 years and 4 months); (iv) Supply declared substance: 1 year, 4 months and 24 days of imprisonment (reduced from 2 years); and (v) 3LA order: 8 months and 12 days of imprisonment (reduced from 12 months).
The sentences imposed on co-offender Kelleher were reduced by 30%. His moral culpability was reduced by his disadvantaged background which moderated the weight of general deterrence and punishment ‘to some degree’: at [125]. This offender is to be sentenced on the basis that he was the person to whom co-offenders Kelleher and Martens answered. The proceeds of crime offence occurred over a period of many months, which was not an offence for which either co-offender was sentenced. There is a warrant for a more severe sentence to be imposed on the offender reflecting the additional criminality involved in his conduct considering his role in the hierarchy of the enterprise and the additional offending conduct he engaged in. Determination
Counsel for the offender conceded at the outset that the gravity of the offending was such that only a sentence of full-time imprisonment would be appropriate in all the circumstances.
The reduction in the offender’s moral culpability moderates to a degree the weight of general deterrence and punishment. The observation I made in Kelleher at [125] applies with equal force in this sentencing exercise: A reduction in the offender’s moral culpability moderates the weight of general deterrence and punishment to some degree. Notwithstanding that finding, they remain compelling considerations. Involvement in the business of drug supply which fuels addiction and all the misery which accompanies it, must be denounced. The maximum penalties in this matter reflect the community’s intolerance for those who seek the rewards of drug trafficking and supply. Those like the offender, prepared to risk involvement in the drug trade, must understand the real potential for severe consequences. I acknowledge the prosecution concession as to the nature of the substances and the capacity for harm they involve as compared to other illicit substances in use in the community.
To which I add that the ‘3LA’ offence and the proceeds of crime offence similarly carry substantial maximum penalties reflective of the gravity of the offending. It has been observed that laundering the proceeds of crime is the “lifeblood of organised crime” (Braisse at [102] citing Tan v the State of Western Australia [2019] WASCA 112 at [50]) and accordingly general deterrence is accorded significant weight. Whilst the source of the proceeds realised by the offender is not entirely clear, his conduct plainly involved a substantial sum of money which supported an aspect of luxury in his lifestyle. I have already embraced the observations of Mossop J in Al-Mothafel extracted above at [83] with respect to the ‘3LA’ offence which I need not repeat.
Any misguided view that the offender might have held when he engaged in the conduct about there being some honour in making controlled drugs available to the community have by now been challenged by the dramatic consequences on his life of his conduct. The offender has now spent a considerable period on remand. I accept that as a person who has not ever interacted with the criminal justice system, his incarceration has brought home to him the seriousness of his conduct and had some deterrent effect upon him. This is perhaps more pronounced in circumstances where the offender’s long-term dream of becoming a father was realised whilst he was in custody. He was, as a direct result of his conduct, absent from the birth of his daughter and will remain absent from her day-to-day life until his released. The offender has demonstrated preparedness to use his time meaningfully whilst in custody and a commitment to ongoing treatment to address the effects of the traumatic events of his childhood over which he had no control. He has strong family support and a history of consistent, successful employment.
The offender has good prospects of rehabilitation. I am satisfied that he does not pose a substantial risk to the community.
The prosecution accepted that there was some ‘overlap’ in the criminality involved in each offence committed as part of one criminal enterprise. Accordingly, it was accepted that some concurrency was necessary as between the drug related offending. That said, the proceeds of crime offence involved substantial additional criminality to the drug related offending which will be necessary to recognise with a degree of accumulation.
The material demonstrated that the offender’s partner and her children will experience significant emotional hardship because of a sentence of full-time imprisonment. Whilst the offender has contact with his young daughter, undoubtedly the capacity for them to build a relationship is frustrated by his incarceration. His partner has been left a single parent. I am satisfied that the offender’s mental health diagnoses mean that the custodial environment is more onerous for him than it would be for an offender without the offender’s mental health challenges. These are matters which mitigate the sentence to be imposed but not to the degree that the sentencing purposes of general deterrence, denunciation and accountability are undermined. Together with my conclusion that the offender does not pose a risk to the community and is capable of reform, consideration of the hardship occasioned by the sentence imposed should properly influence the appropriate non-parole period.
There are two Commonwealth offences. Consistent with the approach taken by Baker J in DPP v Bobb [2025] ACTSC 491 at [61] and [62], the sentence imposed on the Territory offences will take effect first (to comply with s 62 of the Crimes (Sentencing) Act). This is not a matter where the period the offender would have spent on remand by the time I come to sentence him would sufficiently account for the criminality involved in the Commonwealth offences such that the sentence imposed for the Territory offences could commence on the day the offender is sentenced (examples of outcomes where this was the case were referred to by Baker J in Bobb at [61]).
Accordingly, the sentences I impose on the Commonwealth offences will commence at a time in the future (permitted by s 19 of the Crimes Act 1914 (Cth)).
The starting point for Count 1 (CC2023/12189) supply anabolic steroid is 3 years and 6 months of imprisonment, reduced to 2 years 9 months and 18 days.
The starting point for Count 2 (CC2023/12264) traffic in large commercial quantity of a controlled drug, namely psilocin, is 4 years and 6 months of imprisonment, reduced to 3 years 7 months and 6 days.
The starting point for Count 3 (CC3034/8065) traffic in large commercial quantity of a controlled drug, namely tetrahydrocannabinol (THC) is 4 years of imprisonment, reduced to 3 years 2 months 11 days.
The starting point for Count 4 (CC2024/3237) fail to comply with an order under s 3LA, is 2 years of imprisonment, reduced to 1 year 7 months 6 days.
The starting point for Count 5 (SCCAN 19/2026) deal with proceeds of crime exceeding $1,000,000 or more is 4 years of imprisonment, reduced to 3 years 2 months 11 days.
If a Commonwealth sentence exceeds 3 years I must fix a single non-parole period in respect of it. The effect of which will see the imposition of two non-parole periods in this matter. The Territory offences will have a Territory non-parole period and the Commonwealth offences will have a separate, Commonwealth non-parole period. The offender, when eligible for parole on the Territory offences could not be released until he is eligible for release by operation of the Commonwealth non-parole period. The non-parole period for the Commonwealth offences will be set taking into account the period the offender will already have spent in custody by the time the Commonwealth sentences commence.

• A package addressed to [redacted] of Coolum QLD, containing a 10 ml vial of Durabol (Nandrolone Phenylproprate) 200mg and a 10 ml vial of T-entbolin (Testosterone Enanthate) 300 mg with sender details of [redacted]; • A package addressed to [redacted] of Surfers Paradise QLD, containing two 10 ml vials of T-entbolin (Testosterone Enanthate) 300 mg, with sender details of [redacted]; • A package addressed to [redacted] of Moranbah, QLD containing five 10 ml vials of Durabol (Nandrolone Phenylproprate) 200mg and five 10 ml vials of T-entbolin (Testosterone Enanthate) 300 mg, with sender details of [redacted]; • A package addressed to [redacted] of Diddillibah, QLD, containing three 10 ml vials of OzPharm Labs branded Test E 250 (Testosterone), with sender details of [redacted]; • A package addressed to [redacted] of Southport, QLD, containing two 10 ml vials of Sustanbolin 300mg (Testosterone), with sender details of [redacted]; • A package addressed to [redacted] of Kippa Ring, QLD, containing one box of 100 tablets of Stanobol 200mg and a box containing 100 tablets of Nexnos Pharma brand Clenbuterlin (Clenbuterol HCL) 40 mcg, with sender details of [redacted]; • A package addressed to [redacted] of South Mackay, QLD, containing a 10 ml vial of Sustanon 250 mg, a 10 ml vial of OzPharm Labs branded Parabolin (Trenbolone blend) 200mg and a box containing 100 tablets of Nexnos Pharma branded Clenbuterlin (Clenbuterol HCL) 40 mcg, with sender details of [redacted]; • A package addressed to [redacted] of Euramo, QLD, containing a 10 ml vial of OzPharm Labs branded Deca 250 mg (Nandrolone Decanoata) and a 10 ml vial of OzPharm Labs branded Sustanon 250 mg (Testosterone Sustanon), with sender details of [redacted]; • A package addressed to [redacted] of Broadbeach Waters, QLD, containing a 10 ml vial of OzPharm Labs branded Test E 250 mg and a box containing 100 tablets of Nexnos Pharma branded Clenbuterlin (Clenbuterol HCL) 40 mcg, with sender details of [redacted]; • A package addressed to [redacted] of Norman Gardens, QLD, containing three 10 ml vials of OzPharm Labs branded Test E 250 mg and a box containing 100 tablets of Nexnos Pharma branded Clenbuterlin (Clenbuterol HCL) 40 mcg, with sender details of [redacted]; • A package addressed to [redacted] of Karratha Western Australia, containing four 10 ml vials of Sustanon 250 mg (Testosterone Sustanon - OzPharm Labs brand), three 10 ml vials of Tren A 100 mg (Trenbolone Acetate - OzPharm Labs) and four vials of Deca 250 mg (Nandrolone Decanoata - OzPharm Labs brand), with a sender details of [redacted]; • A package addressed to [redacted] of Oakdowns, Tasmania, containing five bottles of 50 tablets of Pfizer brand Xanax 2mg (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of North Haven, NSW, containing eight 10 ml vials of OzPharm Labs branded Sustanon 250 mg (Testosterone Sustanon), a bottle containing 100 tablets of Nexnos Pharma branded Dianabol 100mg (Methandienone), a bottle containing 100 tablets of OzPharm labs branded Proviron 25 mg tablets, four 10mg vials of OzPharm Labs branded NPP 100mg (Nanadralone Phenylpropionate), three blister packs containing 10 Tamoxifen Citrate tablets and a box containing ten unlabelled vials with an unknown white substance inside each, with sender details of [redacted]; • A package addressed to [redacted] of Hunterview, NSW, containing two 10 ml vials of OzPharm Labs branded Test E 250 mg, six 10 ml vials of OzPharm Labs branded Test C 200mg (Testosterone Cypionate) and two 10 ml vials of OzPharm Labs branded Deca 250mg (Nandrolone Decanoata), with sender details of [redacted]; • A package addressed to [redacted] of Traralgone, Victoria, containing five boxes of 50 tablets of Valpam 5mg (diazepam 5mg), a box containing 50 tablets of Nexnos Pharma branded Armidex 2mg (Anastrozole) and two bags of High Society branded THC gummies, with a sender details of [redacted]; • A package addressed to [redacted] of Umina Beach, NSW, containing 15 packets, each weighing 60 grams, of PSI branded 'Cookies and Cream' flavoured psilocybine chocolates, with sender details of [redacted]; • A package addressed to [redacted] of Bodalla, NSW, containing one bottle of 50 Pfizer brand Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Hallett Cove, South Australia, containing two 10ml vials of OzPharm Labs branded Test E 250 mg (Testosterone Enanthate), with sender details of [redacted]; • A package addressed to [redacted] of Holt, NSW, containing two bottles of 50 Pfizer brand Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Horsley, NSW, containing two 10 ml vials of OzPharm Labs branded Test E 250 mg (Testosterone Enanthate), with sender details of [redacted]; • A package addressed to [redacted] of Lara, Victoria, containing two boxes of 50 Nexnos Pharma branded Oxybol 50 mg tablets (Oxymetholone), with sender details of [redacted]; • A package addressed to [redacted] of Chadstone, Victoria, containing ten 10 ml vials of OzPharm Labs branded Test E 250 mg (Testosterone Enanthate), one box of 100 Nexnos Pharma branded Anavarabol 20mg tablets (Oxandrolone) and one bottle of 50 Nexnos Pharma branded Cialis 10mg tablets (Tadalafil), with sender details of [redacted]; • A package addressed to [redacted] of Bilambil Height, QLD, containing eight blister packs, each containing 10 Tapentadol Hydrochloride 200mg tablets, with sender details of [redacted]; • A package addressed to [redacted] of Umina Beach, NSW, containing 15 packets, each weighing 60 grams, of PSI branded 'Cookies and Cream' flavoured psilocybine chocolates, with sender details of "[redacted]"; • A package addressed to [redacted] of Bellebird Park, QLD, containing three 10 ml vials of Nexnos Pharma branded Sustanbolin 300mg (Testosterone Combination), with sender details of [redacted]; • A package addressed to [redacted] of Annerely, QLD, containing one 10 ml vial Nexnos Pharma branded T-entbolin 300 mg (Testosterone Enanthate) and one 10 ml vial of Nexnos Pharma branded Nandrolin 300mg (Nandrolone Decanoate), with sender details of [redacted]; • A package addressed to [redacted] of Nerang, QLD, containing three boxes of 100 tablets of Nexnos Pharma branded Clenbuterlin (Clenbuterol HCL) 40 mcg, one box of 100 Nexnos Pharma branded Anavarbol (Oxandrolone) 20 mg tablets, one 10 ml vial of Nexnos Pharma branded Primbolin 200 mg (Methenolone Enanthate), two 10 ml vials of Nexnos Pharma branded Durabol 200mg (Nandrolone Phenylpropiorate), one 10 ml vial of Nexnos Pharma branded Sustanbolin 300mg (Testosterone Combination), two 10 ml vials of Nexnos Pharma branded Parabolin-E 200 mg (Trenbolone Enanthate) and one bottle 100 OzPharm Labs branded Proviron 25mg tablets, with sender details of [redacted]; • A package addressed to [redacted] of Allambie Heights, NSW, containing one box of 50 Valpam 5mg tablets (Diazapam 5mg) with sender details of [redacted]; • A package addressed to [redacted] of Mascot, NSW, containing two 10 ml vials of OzPharm Labs branded Test E 250 mg (Testosterone Enaanthate), two 10 ml vials of OzPharm Labs branded Sustanon 250 mg(Testosterone Sustanon) and two 10 ml vials of OzPharm Labs branded Tren A 100 mg (Trenbolone Acetate), with a sender name of [redacted]; • A package addressed to [redacted] of Roxburgh Park, Victoria, containing a box containing 50 Clomiphene 20mg tablets and a bottle containing an unknown crystalline substance, with sender details of [redacted]; • A package addressed to [redacted] of Yarraville, Victoria, containing one 10ml vial of OzPharm Labs branded Test E 250 mg (Testosterone Enaanthate), one 10 ml vial of OzPharm Labs branded Mast E 200 mg (Drostanolone Enenthate) and one 10 ml vial of OzPharm Labs branded Masteron 100mg (Drostanolone Propionate), with sender details of [redacted]; • A package addressed to [redacted] of Carlingford, NSW, containing one bottle of 50 Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Kanimbla, Qld, containing one box of 50 Nexnos Pharma branded Oxybol 50 mg tablets (Oxymetholone), with sender details of [redacted]; • A package addressed to [redacted] of Port Macquarie, NSW, containing five bottles of 50 Pfizer brand Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Launceston, Tasmania, containing one bottle of 50 Pfizer brand Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Capel, WA, containing three boxes of 100 Nexnos Pharma branded Anavarbol 20 mg tablets with sender details of [redacted]; • A package addressed to [redacted] of Randwick, NSW, containing a box of 100 Nexnos Pharma branded Anavarabol 20mg tablets (Oxandrolone) with sender details of [redacted]; • A package addressed to [redacted] of Hillside, Victoria, containing two 10 ml vials of OzPharm Labs branded Test C 200mg (Testosterone Cypionate), one 10 ml vial of OzPharm Labs branded Primobolan 100 mg (Methenolone Emanthate), two vials of Nexnos Pharma branded Fina 100mg (Trenbolone Acetate) and two 10 ml vials of Nexnos Pharma branded Banabolone (Boldenone Undercyclenate), with sender details of [redacted]; • A package addressed to [redacted] of Roxburth Park, Victoria, containing five 10 ml vials of OzPharm Labs branded Test E 250 mg, two 10 ml vials of OzPharm Labs branded Tren A 100 mg (Trenbolone Acetate), one 10 ml vial of OzPharm Labs branded Tren E 200 mg (Trenbolone Enanthate), two 10 ml vials of OzPharm Labs branded Test P (Testosterone Propionate), one 10 ml vial of Nexnos Pharma branded Durabol 200mg (Nandrolone Phenylpropiorate) and three blister packs containing 10 Tamoxifen Citrate tablets, with sender details of [redacted]; • A package addressed to [redacted] of Bendigo, Victoria, containing two bottles of 50 Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Coomera, QLD, containing one vial of OzPharm Labs Test E 250 mg(Testosterone Enaanthate) and one 10 ml vial of OzPharm Labs branded Tren E 200 mg (Trenbolone Emanthate), with sender details of [redacted]; • A package addressed to [redacted] of Rockingham, WA, containing three 10 ml vials of Nexnos Pharma branded T-Entbolin 300mg (Testosterone Enanthate), with sender details of [redacted]. Annexure B: list of packages seized on 7 December 2023

• A package addressed to [redacted] of a Palm Beach Qld address, containing two 10 ml vials of OzPharmLabs branded Sustanon 250 (testosterone isocaproate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Drysdale Victoria address, containing two 10 ml vials of TEST E 250 (testosterone enanthate) and four OzPharmLabs branded MAST E 200 vials (drostanolone) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of an Alexandria NSW address, containing two 10 ml vials of Nexnos Pharma brand 300mg T-ENTBOLIN (testosterone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Pemulwuy NSW address, containing two 10 ml vials of OzPharmLabs branded TEST E 250 (testosterone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of Malvern Victoria address, containing two blister packs of 10 tablets of Tadalafil 20mg and one 10 ml vial of Notorious Labs branded TREN (trenbolone) from sender [redacted], Broadbeach QLD; • A package addressed to [redacted] of a Maroochydore QLD address, containing a bottle of 30 NATCO branded Exemestane tables from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Towradgi NSW address, containing one bottle of Nexnos branded 100 Clenbuterlin tablets, two 10 ml vials of Nexnos branded T- ENTBOLIN 300 mg (testosterone enanthate) and one bottle of 100 OzPharmLabs branded Anavar 10mg tablets (oxandrolone) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Cardiff Heights NSW address, containing two 10 ml vials of OzPharmLabs branded TEST E 250mg (testosterone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Howes Creek Victoria address, containing two bottles of 50 tablets of Nexnos Pharma branded 10 mg Cialis Tadalafil from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of an Acacia Ridge QLD address, containing two 10 ml vials of OzPharmLabs branded Sustanon 250 mg (testosterone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Clayfield Qld address, containing two vials of OzPharmLabs branded TEST E 250 (testosterone enanthate) and one bottle of 50 Pfizer branded Xanax 2mg tablets (alprazolam) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of Nerang Qld address, containing one bottle of 100 Nexnos branded Clenbuterlin tablets (Clenbeuterol), one 10 ml vial of OzPharmLabs branded DECA 250 (nandrolone decanoate) and one 10 ml vial of Nexnos branded T- ENTBOLIN 300 mg (testosterone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Nangor NSW address, containing four blister packs of 10 Fortune Health Care branded Tapentadol Hydrochloride 200 mg tabletsfrom sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Richmond NSW address, containing two blister packs of four Cabergoline .5mg tablets and a box of 30 Letrozole 2.5mg tablets from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Teesdale Vicotria address, containing two vials of OzPharmLabs branded MAST E 250 MG (drostanolone) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of Five Dock, NSW address, containing two bottles of 50 Nexons branded Oxybol 50mg tablets (oxymetholone), two bottles of 50 Nexons branded Clenbuterlin 40mcg tablets (Clenbeuterol) and two bottles of 100 Nexnos Pharma branded Dianabol 20mg tablets (methandrostenolone) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of Milton Qld address, containing two 10 ml vials of Nexons branded Dihydroboldenone 100mg (synthetic testosterone), one 10 ml vial of OzPharmLabs branded TEST E 250mg(testosterone enanthate), one 10 ml vial of OzPharmLabs branded EQUIPOSE 250 (boldenone undecylenate), one 10ml vial of Nexons branded TEST 325 (testosterone blend) and two blister packs of 10 Tadafadil 20mg tablets from sender [redacted], Punchbowl NSW. • A package addressed to [redacted] of Mountain Creek Qld address, containing one 10 ml vial of OzPharmLabs branded TEST E 250 (testosterone enanthate), two 10 ml vials of OzPharmLabs branded DECA 250 (nandrolone decanoate) and one bottle of CBD oil from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of North Haen NSW address, containing five 10ml vials of OzPharmLabs branded SUSTANON 250 (testosterone isocaproate), five 10 ml vials of OzPharmLabs branded TEST E 250 (testosterone enanthate) one bottle of 100 Nexnos branded Dianabol 20mg tablets (methandrostenolone), one bottle of 100 OzPharmLabs branded PROVEN 25 mg tablets, one bottle of 50 OzPharmLabs branded ANAVAR 15 mg tablets (oxandrolone), ten vials of a white unknown substance and three blister packs of 10 Modafinil 200mg tablets from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of Brighton LeSands address, containing three vials of OzPharmLabs branded SUSTANON 250 (testosterone isocaproate), three 10 ml vials of OzPharmLabs branded MAST E 250mg (drostanolone), one 10 ml vial of OzPharmLabs branded TEST E 250 (testosterone enanthate), two blister packs containing 10 Jeerima brand lsotretinon 20mg capsules, two Samanli brand 4 gram tubes of Oligopeptide powder and five blister packs containing 10 Tamoxifen 20mg tablets from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] or Bunbury Western Australia address, containing one box of 50 Nexnos brand Tamoxifei Citrate (tamoxifen) 20 mg tablets, one bottle of 30 Exemestane tablets and a small vial of Human Chorionic Gonadotrophin (HCG) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Malabar NSW address, containing five 10 ml vials of OzPharmLabs brand SUSTANON 250 (testosterone isocaproate), five 10 ml vials of OzPharmLabs brand DECA250 (nandrolone decanoate) and one box of 500 Nexnos brand Tamoxfiei Citrate tablets (tamoxifen) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Sheffield Tasmania address, containing one bottle of 50 Pfizer brand Xanax 2mg tablets (alprazolam) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Penrith NSW address, containing one bottle of 50 Pfizer Xanax 2mg tablets (alprazolam) from sender [redacted] Punchbowl NSW; • A package addressed to [redacted] of Leichhardt NSW address, containing one bottle of 50 Pfizer brand Xanax 2mg tablets (alprazolam) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Bellbird QLD address, containing three 10 ml vials of OzPharmLabs brand SUSTANON 250 (testosterone isocaproate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Muswelbrook NSW address, containing two 10 ml vials of OzPharmLabs brand TEST C 200 (testosterone cypionate) and one 10 ml vial of MAST E 200 (drostanolone) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Clyde North Victoria address, containing eight blister packs of ten Tapentadol Hydrochloride 200 mg tablets from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Warners Bay NSW address, containing four 10 ml vials of Oz PharmLabs brand TEST E 250 (testosterone enanthate), four 10 ml vials of DECA 250 (nandrolone decanoate) and two 10 ml vials of TREN E 250 (trenbolone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Bellpost Hill Victoria address, containing four 10 ml vials of OzPharmLabs brand TEST E 250 (testosterone enanthate) and one bottle of Nexnosbrand 100 Dianabol 20mg (methandrostenolone) tablets from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a BundaII QLD address, containing nine 10 ml vials of MAST E 200 (drostanolone), two 10 ml vials of TEST E 250 (testosterone enanthate), five 10 ml vials of TEST P 100 (testosterone propionate), three 10 ml vials of NPP100 (nandralone phenylpropionate) and four boxes containing ten small vials of a white substance. Annexure C: list of substances seized on 8 December 2023

• 1X BOTTLE MOLNUVID 200MG 40 CAPSULES • 3X VIALS OF MELANOTAN 10MG • 1X BOX OF CLENBUTEROL 40MG (100 TABLETS) • 1X BOTTLE ANAVAR 10 10MG • 3X BLISTER PACK SHEETS "GMP" TABLETS (150 TABLETS) • 4X ROLLS HEART SHAPED BRANDED TABLETS • 4X BLUE PILLS SILDENAFIL CITRATE • 1X BLISTER PACK PAIN-O-SOMA 500MG (7 TABLETS) • 2X BLISTERPACK TADALAFIL 20MG (8 TABLETS) • 2X IGET KING VAPES • 1X BOTTLE DIANABOL 20MG (100 TABLETS) AND 1X BOTTLE CIALIS 10MG (SO TABLETS) • 1X BOTTLE CBD OIL "HIGH SOCIETY" 30ML • 1X PACK HIGH SOCIETY THC GUMMYS • 1X BOTTLE OF UNLABELLED LIQUID • 1X SYRINGE WITH LIQUID RESIDUE • 3X UNKNOWN TABLETS • GMP UBLABELLED TABLETS BLISTER PAC • SILDENAFIL CITRATE 100MG TABLETS X 7 • TAMOXIFAN CITRATE 20 MG X 100 TABLETS • 9 X TABLETS TADALAFIL 20MG • 1 X GREEN PLASTIC BOTTLE - UNLABELLED CAPSULES • 24 X BLISTER PACK OF PINK TABLET I 15 TAB EACH BLISTER WITH 10 MISSING - IBUPROFEN • 8 X WHITE BOXES CONTAINING 10 VIALS EACH - CONTAIN WHITE POWDER- UNKNOWN • 8 X BLISTER PACKS 15 X TABLETS PREGABALIN CAPSULES 300MG • 1 X LARGE BAG WHITE/CREAM POWDERED SUBSTANCE & SPOON • 3 X BLISTER PACKS 10 X TABLETS TADALAFIL 20MG • 24 TABLETS OF VALPAM 5MG • 100 X TABLETS OF STANOBOL • 27 X TABLET OF LETROZOLE IP 2.5MG • 6 X UNLABELED BOTTLES OF PILLS • 2 X BOTTLES VYVANSE TABLETS • 7 X VIALS OF MELANOTAN • 2 X VIALS DIANABOL • 9 X VIALS OF PENTADECAPEPTIDE • 1 X BOX TAMOXIFEN CITRATE TABLETS • 1 X BOTTLE MESTEROLONE TABLETS • 12 X TAPENTADOL HYDROCHLORIDE TABLETS • 1 X BOTTLE STANOBOL TABLETS • 8 X VIALS MECHANO GROWTH FACTOR & 10 X VIALS BACTERIO STATIC WATER • 1 X VIAL CLEAR LIQUID • 4X VIALS WHITE POWDER • 1 X BOTTLE S-23 SARM TABLETS • 1 X BOX CATERGOLINE TABLETS • 14 X TABLETS MESTEROLONE • 6 X TABLETS DIAZAPAM • 1 X CLIPSEAL BAG CONTAINING 8 X BLUE/PINK CAPSULES • 4 X TABLETS DICLOTENEE TABLETS • 1 X BLUE TABLET • 2 X BOTTLES SARM CARDARINE • 30 X SILDENAFIL CITRATE TABLETS • 598X VIALS TEST BASE 75 CLEAR LIQUID • 599X VIALS TEST BASE 75 CLEAR LIQUID • 1600X NEXNOSTROPIN HUMAN GROWTH HORMONE VIALS • 1610 X NEXNOSTRAPIN HUMAN GROWTH HORMONE • 760 X NECNOSTROPIN HUMAN GROWTH HORMONE VIALS • 122 X VIALS VIROME TESTOSTERONE • 2 X BOTTLES ASPEN DEXAMFETAMINE • 1 X BLISTERPACK CABERGOLINE 0.5MG • 1 X BOTTLE THC OIL "QUATRO" BRAND 23MG • 1 X BOTTLE ANTENEX 5 DIAZEPAM 5MG (9 TABLETS) • 1 X BOTTLE MK677 IBUTAMORAN 5 CAPSULES 20MG • 2 X BOTTLES "PURE NMN" (80 CAPSULES TOTAL) 250MG • 1 X BOTTLE TUDCA (35 CAPSULES) 500MG • 1 X BOTTLE "LIONS MAINE" 120ML • 1 X BOTTLE "QUATTRO" CBD OIL • 1 X BOTTLE HIGH SOCIETY CBD OIL • 3 X BLISTERPACKS MESTEROLONE (28 TABLETS) • 1 X PACK WATERMELON THC GUM MIES (lGUM) • 1 X BOTTLE BPC 157 (34 TABLETS) • 1 X TUB CONTAINING 1235 X VIALS MASTE-200 • 1 X TUB CONTAINING 1186 VIALS OF SUSTANON 250 TESTOSTERONE ISOCAPROATE • 1 X TUB CONTAINING 665 VIALS DECANOATE 250 NANDROINE • 1 X TUB 906 VIALS SUSTANON 250 • 1 X TUB 600 VIALS TRENE 200 • 1 X TUB 833 VIALS TRENBOLONE ACELATE 100MG • 1 X TUB 474 BOXES (100 TABLETS EACH) CLENBUTERLIN HCL 40MG • 1 X TUB 938 VIALS EQUIPOSE 250MG • 1 X TUB 353 VIALS TEST P-100 • 1 X TUB 1020 VIALS MENT-50 200MG • 1X TUB 164 BOXES TESTOSTERONE ETHERNATE • 1X TUB 1207 BOXES MPP-100 100MG • 1X CARDBOARD BOX 700 VIALS TEST-E 250 • 1X TUB 1366 VIALS TREN A100 • 1X CARDBOARD BOX 1000 VIALS TESTOSTERONE ENANTHATE 250MG • 1X TUB 900 VIALS TEST-E • 1X CARDBOARD 950 BOTTLES 250MG TEST-E • 1X TUB 1278 BOTTLES MAST-E 200 DROSTABOLONE ENENTHATE • 1X TUB 1099 BOXES MAST-E 200 • 315X PACKETS "HIGH SOCIETY" SOUR APPLE BLOSS BOMBS • 1X TUB 1200 VIALS TRENBOLONE ENANTHATE 200MG • 244X PACKETS HIGH SOCIETY THC GUMMIES (WATERMELON) • 1X TUB 823 VIALS MASTERON - 100 AND 23 VIALS NPP • 96X BOXES TESTOSTERONE PROPIONATE 100MG • 291X BOXES TRENBOLONE ACTATE 100MG • 1X TUB 308 NOTORIOUS LASBS TEST-E 250MG • 1X TUB 85X BOXES NANDROLONE 100MG • 1X TUB 128X NOTORIOUS LABS DECA-A 250MG • 1X TUB 200X BOXES MASTE 200MG • 1X TUB 653X VIALS NOTORIOUS LABS TESTE • 1X TUB 247X VIALS NOTORIOUS LABS TREN-E • 397X BOXES TESTOSTERONE 250ML • 1X TUB 67X BOTTLES LIOTHYROIC - T3 25MG • 1X TUB 545X BOTTLES ANAVA -10 10MG • 1X TUB 83 BOTTLES OXYBOL OXYMETHOLONE 50MG • 1X TUB 82 BOXES 10 VIALS EA PARABOLINE 200MG TRE • 1X TUB 176 BOXES HALOTESTBOL 10MG • 21 BOXES / 50 EA PROVIRANIC MESTEROLONE 25MG • 1X TUB 98 VIALS MASTERBOLIN l00MG • 175 BOXES NANDIOLIN 300MG • 107 BOXES NANDIOLIN 300MG • 55 BOXES ARMIDEXIC2MGX 50 TABLETS • 1X TUB 235 BOXES/ 50 EACH PROVIRONIC 25MG 100 BOXES /100 EACH TESTOSTERONE 200MG • 1 TUB 54 BOXES/ 100 TABS EA. TESTOSTERONE 200MG • 1X TUB - 110 BOXES - STANAINJECT 50MG • 60 BOXES Ml TESBOL 5MG/50 TABS EACH • 7 x BLISTER PACKS/ 10 EACH CLAMIFENE 50MG • 106 BOXES/ 50 TABLETS EA 20MG CLORIPHEFEI • 1X TUB 50 BOTTLES CLENBUTERLIN 40MG 100 TAB EA BOTTLE • 128 BOXES/100 TABS X 20 MG STANOBOL • 146X 200MG DURABOL, 2X 300MG DURABOL 1X 100MG DURABOL 15X 150MG DURABOL • 343X VIALS GANAOBOLONE 300MG • 153 X PACKETS TAMOXIFEN CITRATE • 270X VIALS PRIMBOLIN 200MG • 21X VIALS T-PROBOUN 100-lO0MG • 206X VIALS VIROME l00MG • 283X VIALS PARABOLIN 200MG • 188X VIALS SUSTABOLIN TESTOSLERONE • 51X BOXES SUSTEN-DEPO 10XlML PER BOX) • 34 BOXES (10XlML DOSES) RX TEST 325 • 376X VIALS TEST-325 325MG • 163 VIALS DIHYDROBOLDENEONE 100MG • 168 VIALS MASTERBOLONE • 1X BOX STANOBOL TABLETS • 101X BOTTLES MENT-50 TRESTOSTELONE 50MG • 177X DHB-100 lO0MG • 322 X VIALS PARABOLIN - E 200MG • 371 X VIALS SUPERBOLIN 50MG • 127 VIALS TEST-E 250 • 252 X BOXES T-ENTBOLIN 300MG • 108 X VIALS SUSTANON 250MG • 304X VIALS TREN - A • 233X BOXES EQUIPOSE 250MG • 31 X VIALS DECA-250 250MG/10ML • 513X VIALS MAST-E 200MG • 192 X CIALS TREN-E 200MG • 270 X VIALS NPD-100 100MG • 397 X VIALS TREN-A 100MG • 184 X VIAL TEST-P 100MG • 297X VIALS MASTERONE 100MG • 194 X VIALS MAST-E 200MG • 322 X VIALS TEST-C 200MG • 521 X VIALS PRIMOBOLAN 100MG • 226 X VIALS TEST BASE 7SMG • 237 X VIALS TEST BASE 7SMG • 82 X BOTTLE PROVISION 25MG • 242 X BOTTLES XANAX 2MG • 187 X VIALS HCG 5000 IU • 57 BOXES (10 VIALS PER BOX) HGH lSIU • 137 X BLISTER PACK SILDENAFIL 100MG (10 PACKS) • 162 X BLISTER PACKS TADALAFIL TABLETS 20MG • 80 X VIALS NANDORLIN • 83 X BOTTLES RAD-140 10MG • 249 X BOTTLES KALMA 2MG • 18 X VIALS 5-23 10MG • 640 BLISTERPACKS (10 TABLETS EA) 200MG MODAFINIL • 27 BOTTLES RAD-140 10MG • 220 X VIALS GANABOLONE 300MG • 74 x VIALS MASTERBOLIN 100MG • 64 X VIALS TESTOSTERONE COMBINATION 300MG • 108 X BOTTLES OSTARINE (60 TABLETS) 10MG • 416 X BOXES SARMS - OSTARI - BOL (50 PER BOX) 10MG • 88 X BOTTLES OSTARINE (60 TABLETS EA) 10MG • 102 X VIALS SARMS - OSTARI - BOL 10MG (SO PER BOX) • 15 BOXES OLIGOPEPTIDE IYOPHILIZED POWDER (80 PER BOX) • 74 X BOTTLES GW 501516 (60 TABLETS EA) • 657 BLISTERPACKS (lOEA) TYPENTA 200 MG • 68 BLISTERPACKS (lOEA) TAPADAY 200MG • 50 BOTTLES MK677 10MG (60 TABLETS EA) • 452 BLISTERPACKS (lSEA) TELMISARTHEN 40MG • 85 X BOXES (30 EA) FEMARIC 28MG • 1901X BLISTERPACKS (lOEA) TAMOXIFEN-CITRATE 20MG • 3 X VIALS DROSTANOLONE ENENTHATE 200MG (10ML PER VIAL) • 1 X ARMODAFINIL TABLETS • 999 OZPHARMLABS TEST E • 14 BOXES OF LIFTHENG SOX BOXES OF NPP100 • SAMAULI BOXES, OLIGOPETIDE 4G X 20 22 X QUATTRO THC OIL • 502 X TREN E200 • 411 X DECA 250 • 200 x SUSTANON 250 • 15 X 50 + 1 X 35 BOXES MAST E 250 • SUSTANON 250 X 1000 BOXES • 5 BOXES PEARL POWDER & CONTENTS • 2 X BOTTLES EXEMESTANE 25MG X 30 • 3 X BOTTLES CIALIS LONG X SO TABS • 18 X QUATTRO THC OIL • SUSTANON 250 (16X50) (1X50) (1X47) (1X34) BOXES • 6 X BOXES OLIGOPEPTIDE SUS • 28 SAMANLI 4G X 20 • 20 X BAGS SUSTANON (19X50) (1X47) • 1 X BOX TASALAFIL TABLETS 20MG • 1 X VIAL WINSTROBOLIN 50 TABS • CIALIS LONG X 50 TABS X 518 BOTTLES • PARABOLAN 200MG X 24 BOXES • TEST E 250 - 1120 BOXES • TRENA 100 (12X50) (1X35) BOXES • 2 X BOXES DAMASCUS ROSE HYDROSOL • 6 X LYOPHILIZED POWDER (BOXES) TREN E 200 - 50 BOXES • PSI CHOCOLATE - 30 BLOCKS • NPP100 - 20 BAGS X 50 BOXES EPC157 - 59 BOXES • SUSTANON 250 - 247 BOXES • TEST E 250 - 432 BOXES • TRENA 100 - 400 BOXES LIFEHEAVY ICE MASKS - 2 BOXES QUATTRO CBD OIL X 20 • TEST 325 - 232 BOXES • 3 X BPC 157 I 2 VIALS NEXNOSTROPIN I 1 UNLABLLED VIAL • 5 EPIPENS • TREN E 200 - 774 BOXES • 1 QUATTRO CBD OIL • 1 HIGH SOCIETY CANNABIS VAPE • 2 BLISTER PACKS OF LETROHEAL 2.5MG • 10 X 1ML EPIPENS I 1.5ML EPI PEN I 6 TOBLERONE CHOCOLATE SIKMAFAL CITRATE - 2200 TABS • TEPENTADOL 200MG - 286 PACKETS TEST P 200 - 375 BOXES • SUSTANBOLIM 300 MG - 1 BOX • OMNITROWLE • 20 UNLABELLED BOXES I 13 UNLABELLED BOTTLES • 5 X CBD OIL BOTTLES • DIANABOL 20MG - 100 TABLETS • 1 X KALMA 2MG BOTTLE • 1 BOX LEROZOLE 2.5MG • 1 CBD OIL VAPE • LEVOTHYROXIME - 39 BOXES (100 TABLETS PER BOX) • 19 CBD OIL BOTTLES • LIOTHYRONINE SODIUM - 49 BOXES • SILDENAFIL CITRATE 100MG TABLETS (BLISTER PACKET OPEN) • CIALIS 10MG - 1 BOTTLE • NPP 100 - 475 BOXES • 4 BLISTER PACKS VIDALISTA • 9 BOTTLES ANADRORAL • 50 BOXES OF 100 EUTHYROX 50 • 1 BOX CLOMIFENE CITRATE 30 TABLETS • 4440 X CLOMIFENE CITRATE • 77 BOXES HIGHLY PURIFIED CLORIONIC GONADOTROPHIY • 110 BLISTER PACKS OF CAVBISET TABS • 461 OXYBOL NUMEROUS STEROIDS • 42 BOXES CHORION IC GONADOTTROPIN • 92 QUATTRO CBD • 230 ANASTROZOTE 1MG TABS • 1 BOX ISOTRETINOIN CAPS, 30MG • 231 BLISTER PACKS OF ISOTRETINOIN CAPSULES • 2 MELANOTAN 2 (10MG) • 9 MGF 5MG • BZ 15 X IGFI (1MG) 25 HEXARELIN • 16 GLYCIPHASE 850 • 2 ARMIDEXIC 2MG X 50 TABLETS • 114 PROVIRONUM BLISTER PACKS • 208 BLISTER PACKS OF ANASTROZOLE TABS 1MG • 695 TABS OF PRESABALIN 300MG • 300 TABS ZOPICLON 20MG • 9370 TABS OF TAMOXIFEN CITRATE • 39 BLISTER PACKS OF VARIOUS SUBSTANCES • 98 BLISTER PACKS OF FLIBAN • TAMOTIFEN - 9 BLISTER PACKS • 1 GREEN BOTTLE OF CAPSULES • TADALAFIL 20MG - 9 BLISTER PACKS • ANASTROZOLE 1MG - 12 • PSI CHOCOLATE -10 BLOCKS • 449 BOXES OF FEWTBOLIN 300MG • ASSORTED VIALS, BLISTER PACKS • 492 BOTTLES XANAX • NUMEOUS STEROID ITEMS • 1560 TABS RALOXIHEAD 60MG • 50 TABS CLONIFENE TABS • 14 X 10 BLISTER PACKS CORISPRODOL • 20 VIALS OF PENTADELAPEPTIDE • VARIOUS SUBSTANCES • 134 GREEN BOTTLES CONTAINING CAPSULES • 180 TAMOXIFEI, 50 X NEXOS • 1001 TREN-A 100 • 2490 TABLETS OF CETROZOLE 2.5MG • 1 VIAL HEXARELIU SMG • VARIOUS SUBSTANCES • 208 CONTAINERS OF NUMEROUS STERIODS (50 TABS EACH) • 10 BLISTER PACKS ZOPICLANE 20MG • 1 X CLIPSEAL BAG CONTAINING ASSORTED VIALS • VARIOUS STEROIDS • 2 X VAPES • 10 VIALS MASTERBOLENE 10 ML • 41 VIALS OF MASTERBOLONE 10ML • OPEN HIGH SOCIETY THC GUMMIES • FLIBAMSERIN 100MG OPEN BLISTER PACK • 17 VIALS OF HIGH SOCIETY CBD OIL • 7 UNLABELLED VIALS OF LIQUID • 1 VIAL OF TEST 325 • 1 BOX CABERGOLINE C18 TABS • 1 BOTTLE OF DIAUABORAL • 1 BOTTLE OF Ml TESBOL • 1 VIAL OF EQUIPOLE 250 • 1 VIAL TREN-A • 12 X BOXES + 47 BOTTLE OF EXENESTON • 146 X 4 BLISTER PACKS OF CABERGOLONE CABERDOST O.SM • 100 BLISTER PACKS ASTROZOLE TABLETS • 410 BOXES CONTAINING 10 VIALS OF UNKNOWN SUBSTANCE • 135 HIGH SOCIETY VANILLA CANNABIS VAPES • 60 PACKS OF PENTADECA-PEPTIDE 5MG VIALS • 100 BLISTER PACKS ANASTROZOLE • 10 X 4 BLISTER PACKS CABERGOLINE CABGOLIU 0.5MG • 220 X 4 BLISTER PACKS OF CABERGOLINE DOSTILHEAL 0.5MG • 1 BLISTER PACK OF PREGABOLIN • LIOTHROIC/T3 X 330 BOTTLES & LIOTHYROIC SODIUM X 25 BOTTLES • STANOBOL X 150 BOXES • 140 DIANABOL X 473 BOTTLES • RX TEST 325 X 48 BOXES • 24 BOXES OF UNKNOWN WHITE POWDER • 24 BOXES OF UNKNOWN WHITE POWDER • 1017 BLISTER PACKS+ 10 BOXES OF ARASTROZOLE • 4 HIGH SOCIETY RELIEF CBD OILS • 119 VAPE PENS • 806 VIALS WITH YELLOW LIDS CONTAINING UNKNOWN SUBSTANCES • 2350 VIALS OF UNKNOWN SUBSTANCE IN FOIL • 60 BOXES OF PENTADECAEEPTIDE B 5MG • 10 VIALS OF PROGONALZOOP • 19 BAGS - 50 TEST E • 2 X CLIP SEAL BAGS OF BROWN POWDER • 1 X CLIP SEAL BAG OF YELLOW CRYSTALLINE SUBSTANCE • 1 X UNLABELLED BOTTLE CONTAINING LIQUID

DPP v Kustic

At a glance

Court

Decision date

Before

Catchwords

Source

Catchwords

Judgment

Parties

Legislation Cited (5)

Cases Cited (12)